As FDA Considers Pulling Phenylephrine, Doctors Consider Patient Alternatives

After a U.S. Food and Drug Administration (FDA) panel this week advised against phenylephrine as an effective decongestant when taken orally, doctors are reconsidering what to prescribe patients for a stuffy nose.

After a U.S. Food and Drug Administration (FDA) panel this week advised against phenylephrine as an effective decongestant when taken orally, doctors are reconsidering what to prescribe patients for a stuffy nose.

The FDA advisory panel said oral forms of phenylephrine – a nasal decongestant commonly found in over-the-counter drugs like Nyquil, Benadryl, Sudafed and Mucinex – don’t work. 

The panel said the ingredient does not absorb into the body as previously thought and is no more effective than a placebo when taken in pill form.

Dr. James Clark, an allergy and immunology specialist with Charleston Area Medical Center, said while they take longer to work, over the counter steroid nasal sprays are a safe and effective alternative. However, they require patience on the part of the patient.

“One of the best ways to alleviate nasal congestion is the regular use of a steroid nasal spray, and those are all over the counter now,” Clark said. “The problem is those medicines don’t work right away, you have to use them regularly for a few days minimum before you start to see improvement.”

Examples of steroid nasal sprays include Flonase, Rhinocort, Nasonex and Nasacort. They work by helping to minimize allergy symptoms like sinus congestion, sneezing, itchy or runny nose and itchy/watery eyes.

Clark said most medicines for allergies use a combination of antihistamines and decongestants to make them more effective. He said while topical non-steroid decongestants work rapidly, they need consideration because of their rebound effect and propensity for addiction. 

Rebound congestion is caused by using nasal decongestant sprays for more than three days in a row. The blood vessels in nasal passageways can become sensitized to the active ingredients and react by swelling as the medication wears off.

Non-steroid decongestants include Naphazoline, which works by temporarily narrowing the blood vessels, and Oxymetazoline, which is sold under the brand name Afrin, works the same way. It is used for nasal congestion, allergic reactions of the eye, and facial erythema associated with rosacea. 

Clark said oral decongestants like Sudafed that contain pseudoephedrine work well, but have purchase restrictions. In 2006, over-the-counter medications containing pseudoephedrine were moved behind the pharmacy counter because of concerns they could be used to make illicit methamphetamines. Sudafed PE which contains phenylephrine is readily available over the counter. 

Clark said he is not a big fan of decongestants in general because of the way they work.

“Number one, they shrink down the caliber of a blood vessel,” Clark said. “What causes congestion is blood vessels being swollen. And when you shrink down the caliber of a blood vessel you increase the pressure in there so decongestants like Sudafed have the potential to increase blood pressure, which isn’t good in older people, and also in males it can cause problems with the prostate.”

Last year sales of products containing phenylephrine totaled nearly $1.8 billion.

If the FDA takes the panel’s advice and pulls phenylephrine from the market, manufacturers would be required to remove all products containing the ingredient from store shelves.

Manufacturers like Procter & Gamble and Johnson & Johnson, as well as pharmacy chains, which sell over-the-counter cold and allergy pills would be affected.

The same panel of researchers that advised the FDA about phenylephrine, questioned the drug’s effectiveness in 2007. 

The FDA allowed the products to remain on the market pending additional research.

What’s Workforce W.Va. All About And Turning A Former Mine Into A City Park On This West Virginia Morning

On this West Virginia Morning, we continue our series “Help Wanted, Understanding West Virginia’s Labor Force,” as Randy Yohe talks with Scott Adkins, acting commissioner of Workforce West Virginia, about the agency’s job seeking services – and how well they are working.

On this West Virginia Morning, we continue our series “Help Wanted, Understanding West Virginia’s Labor Force,” as Randy Yohe talks with Scott Adkins, acting commissioner of Workforce West Virginia, about the agency’s job seeking services – and how well they are working.

Also, Pittsburgh-based environmental issues program The Allegheny Front’s latest story about efforts to convert former mine lands into a city park in Pittsburgh.

And federal approval moves a new COVID-19 vaccine closer to release, a WVU administrator addresses legislators, and the state’s best tourism year.

West Virginia Morning is a production of West Virginia Public Broadcasting, which is solely responsible for its content.

Support for our news bureaus comes from Concord University and Shepherd University.

Listen to West Virginia Morning weekdays at 7:43 a.m. on WVPB Radio or subscribe to the podcast and never miss an episode. #WVMorning

WVU Experts Instrumental In Approval Of New RSV Prevention Medication

Medical experts at West Virginia University are excited about the Food and Drug Administration’s (FDA) approval of Beyfortus as a major advancement to prevent RSV.

Medical experts at West Virginia University are excited about the Food and Drug Administration’s (FDA) approval of Beyfortus as a major advancement to prevent RSV.

Dr. Lisa Costello is an assistant professor in pediatrics at WVU. She said most kids will get RSV in their lifetime.

“For most kids, it’s like a cold, they will have a stuffy nose, cough, there’s a lot of secretions that people get with RSV,” Costello said. “However, for some individuals, RSV can land them in the hospital, and there are certain groups of children who are at higher risk.”

Dr. Mark Polak is a professor of Pediatrics at WVU School of Medicine. He and a team of physicians, nurse practitioners, nurses and pharmacists in the WVU Pediatric Research Unit participated in three pivotal Phase 3 clinical trials.

“In you and I, we’ve seen RSV so many times that our bodies are strong enough to kind of, like, keep it as a common cold,” Costello said. “But in babies who have an immature immune system, the virus can go from the cold down into the trachea, where it causes bronchitis, or even down into the lungs and causing pneumonia.”

Polak said that while there are similar drugs on the market, Beyfortus can last longer in the body than the typical month antibodies usually last.

“We have a new monoclonal antibody, that isn’t degraded in a month,” Polak said. “It actually may last, I think the latest data is at least 150 days.”

Local families allowed their infants to join the projects, which provided critical data on the safety and efficacy of the monoclonal antibody to prevent severe RSV.

“The results were actually spectacular,” Polak said. “It really made a huge, huge difference in not only preventing hospitalizations but preventing and decreasing the need for families to take their kid to see the doctor.”

Polak said RSV was pervasive last winter and hopes Beyfortus can help families avoid long-term symptoms.

“The CDC is predicting another bad winter for RSV, so this is very timely, that it’s been approved,” Polak said. “And, you know, we’re keeping our fingers crossed that we get it out there. Not just in a high risk population, but every baby who’s less than a year old.”

Appalachia Health News is a project of West Virginia Public Broadcasting with support from Charleston Area Medical Center and Marshall Health.

Exit mobile version